ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,671.35
      1.35%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      08/24/20227:21PMPR Newswire (US)Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)NYSE:ABBVAbbVie Inc
      08/22/202212:58AMTipRanksFive-Star Financial Blogger Zvi Bar is Bullish on These 2 StocksNYSE:ABBVAbbVie Inc
      08/17/20228:45AMPR Newswire (US)Experience the JUVÉDERM® Difference with Allergan AestheticsNYSE:ABBVAbbVie Inc
      08/04/20223:59PMEdgar (US Regulatory)Quarterly Report (10-q)NYSE:ABBVAbbVie Inc
      08/03/20228:45AMPR Newswire (US)FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline DefinitionNYSE:ABBVAbbVie Inc
      08/02/202211:16PMTipRanksSVB Securities Sticks to Their Sell Rating for AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      08/01/20227:05PMGlobeNewswire Inc.Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological DiseasesNYSE:ABBVAbbVie Inc
      08/01/202212:39PMTipRanksAbbVie (ABBV) Gets a Hold Rating from UBSNYSE:ABBVAbbVie Inc
      08/01/202212:39PMTipRanksMorgan Stanley Reaffirms Their Buy Rating on AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      08/01/20226:08AMTipRanksAbbVie Stock Declined 4.2% on Friday Despite Upbeat Q2 PerformanceNYSE:ABBVAbbVie Inc
      07/29/202212:47PMDow Jones NewsAbbVie's Allergan in Pact for Opioid Settlement, NC AG SaysNYSE:ABBVAbbVie Inc
      07/29/202211:58AMDow Jones NewsAbbVie Down Over 6%, on Pace for Largest Percent Decrease Since September 2021 -- Data TalkNYSE:ABBVAbbVie Inc
      07/29/20227:41AMPR Newswire (US)AbbVie Reports Second-Quarter 2022 Financial ResultsNYSE:ABBVAbbVie Inc
      07/29/20222:00AMPR Newswire (US)RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial SpondyloarthritisNYSE:ABBVAbbVie Inc
      07/28/20228:32AMBenzingaBenzinga Before The Bell: Apple's Latest Move For Self-Driving Car Project, Monkeypox Is A National Emergency, Spirit-Jet Blue Merger And Other Top Financial Stories Thursday, July 28NYSE:ABBVAbbVie Inc
      07/27/20229:43AMDow Jones NewsAbbVie Seeks U.S., Europe OK of Rinvoq for Crohn's DiseaseNYSE:ABBVAbbVie Inc
      07/27/20228:45AMPR Newswire (US)AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's DiseaseNYSE:ABBVAbbVie Inc
      07/27/20225:09AMTipRanksBerenberg Bank Maintains a Hold Rating on AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      07/26/20222:00AMPR Newswire (US)European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative ColitisNYSE:ABBVAbbVie Inc
      07/25/20228:00AMPR Newswire (US)AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 ConferenceNYSE:ABBVAbbVie Inc
      07/21/20224:39AMTipRanksAbbVie Fosters Strategic Alliance to Cure GlaucomaNYSE:ABBVAbbVie Inc
      07/20/20223:52PMPR Newswire (Canada)AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib) dans le traitement des adultes atteints de spondylarthrite ankylosante évolutiveNYSE:ABBVAbbVie Inc
      07/20/20223:45PMPR Newswire (Canada)Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Ankylosing SpondylitisNYSE:ABBVAbbVie Inc
      07/20/20223:22PMTipRanksAbbVie Stock: A Superficially-Bullish NarrativeNYSE:ABBVAbbVie Inc
      07/20/20229:56AMTipRanksAbbVie (ABBV) Receives a Buy from BMO CapitalNYSE:ABBVAbbVie Inc
      07/20/20227:00AMPR Newswire (US)AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of GlaucomaNYSE:ABBVAbbVie Inc
      07/18/202210:05AMBusiness WireGenmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NYSE:ABBVAbbVie Inc
      07/18/20222:00AMPR Newswire (US)AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
      07/12/20225:05PMDow Jones NewsADRs End Lower; Teva Pharmaceutical, Banco Santander Trade ActivelyNYSE:ABBVAbbVie Inc
      07/12/202212:39PMDow Jones NewsTeva Pharmaceutical, Abbvie's Allergan Settle Opioid Suit With San Francisco -- UpdateNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV